Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2021-05-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tivozanib works in treating patients with recurrent
ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.